As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insights (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time.

In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:

  • Navigate from VCF to final report with speed, precision, and confidence;
  • Easily issue report addendums without the need for re-running a VCF;
  • Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
  • Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.
About the speaker
Umadevi Thirumurthi, PhD, Associate Director of Global Product Management, Somatic Oncology
QIAGEN Digital Insights
Umadevi Thirumurthi, Ph.D., is the Associate Director of Global Product Management, Somatic Oncology at QIAGEN Digital Insights. Prior to joining QIAGEN in Nov 2022, Dr. Thirumurthi was at Sema4 (now GeneDx), where she played a lead role in the development of their in-house Cancer Knowledgebase to support clinical reporting of the Sema4 Solid Tumor and Whole Exome/Transcriptome tests. During her tenure at Sema4, besides supporting the clinical oncology workflow, she was also instrumental in building tools and software solutions in collaboration with bioinformatics and software units and closely working with the business development, marketing, and product units within Sema4 to assist in launching oncology products into the market. Other past work included identifying novel pathways to target cancer stem cells at Merrimack Pharmaceuticals.Dr. Thirumurthi has a Ph.D. in Cancer Biology from UTHSC MD Anderson Cancer Center and a Master’s in Molecular Biotechnology from Wayne State University.
2024년 4월 4일 목요일
05:00:00 오전 (UTC) - 06:00:00 오전 (UTC)
Duration:60 minutes
Categories
Online webinar
Biomedical Research
Bioinformatics - Interpretation
Bioinformatics
Cancer Research